House of Commons
EDM #2747
Tabled 30 September 2019
2017-19 Session
That this House disagrees with the decision made by the National Institute for Care Excellence to reject the migraine prevention drug Erenumab on the NHS in England, Wales and Northern Ireland; is disappointed by the reasoning that the drug was not cost-effective; believes that the health and well-being of migraine sufferers must take precedence over cost margins; and calls on the Government to overturn that decision in line with the Scottish Medicines Consortium to ensure that all migraine sufferers in the UK are given equal and free access to this promising new treatment.

Signatures (8)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
There are no withdrawn signatures for this Motion